Sanofi has placed an enterprise value of €16m ($17m) on Opella, around 14 times the estimated core earnings (EBITDA) for 2024, as per a 21 October press release.

French drugmaker Sanofi said on Monday it had entered exclusive talks to sell a 50% controlling stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R).

The valuation for Opella is based on an enterprise value of approximately €16 billion, equating to around 14 times its projected EBITDA for 2024. CD&R's offer is binding and fully financed.

Sanofi is in discussions with the French government to address concerns officials raised about a potential sale of a controlling stake in the company’s consumer health business, Opella, to ...

Sanofi and CD&R close Opella transaction, create global consumer healthcare leader Paris, April 30, 2025. Opella today becomes an independent global leader in consumer healthcare, marking a ...

Six months after entering talks with U.S. private equity firm Clayton, Dubilier & Rice (CD&R), Sanofi has closed a deal to sell a 50% controlling stake of its consumer health business Opella for ...

Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a ...

Headquartered in France, Opella employs over 11,000 people, operates in 100 countries with 13 best-in-class and strategic manufacturing sites and four science and innovation development centers.

French drugmaker Sanofi said on Thursday it was "surprised" by a renewed, higher offer for its consumer arm Opella from private equity firm PAI Partners, saying the move came after the bidding ...

Among the penalties is a €40 million fine if Opella stops making its products at two facilities in Lisieux and Compiègne and €100,000 for each layoff that takes place for economic reasons.

Headquartered in France, Opella employs over 11,000 people, operates in 100 countries and manages 13 best-in-class manufacturing sites and four research and innovation centers.

While Opella has long operated as a standalone unit within Sanofi, boasting more than 11,000 employees across 100 countries, Sanofi in October proposed a plan to sell a 50% controlling stake to U ...